bristol-my squibb compani bm engag discoveri develop licens manufactur market distribut
sale pharmaceut nutrit product compani two segment pharmaceut nutrit
pharmaceut segment made global pharmaceut intern consum medicin busi nutrit
segment consist mead johnson nutrit mead johnson primarili infant formula children nutrit busi
januari compani complet divestitur bristol-my squibb medic imag medic imag avista capit
partner june bm acquir kosan bioscienc inc develop oncolog product august compani
complet divestitur convatec busi cidron healthcar limit affili nordic capit fund vii
decemb bm complet sale brand busi egypt glaxosmithklin
rank
return equiti
price book
incom statement summari figur billion
global peer group analysi figur usd
compani
compani
hi
long-term fundament rank
short-term technic rank
rank number list
pharmaceut compani trade today unit state
market capit billion
pharmaceut compani highest total
asset highest revenu
within sector rel low price-to-earnings high p/
strong rel roe roa
compani paid dividend last twelv month
dividend yield high
stock score set
involv valuat size
financi perform
rank accord
averag valu
rank lowest
rank
significantli price discount
day move averag price rang
trade discount
high premium low
invest exactli one year ago worth
capit loss dividend reinvest
stock score set
price perform trade
volum rank
accord averag
valu paramet
highest rank
lowest rank
bristol-my squibb compani place bss rank nyse perform past year percentil rank
bristol-my squibb compani new entrant boston consult group list top innov compani rank
rank mcap march pwc top global compani improv year rank
march
largest revenu ft global
rank newsweek corpor knight capit world greenest compani outstand score
product wast product carbon product
largest revenu forb global
new entrant industri week list world largest manufactur revenu rank
sector total bracket
revenu billion aggreg sector revenu
billion previou year
net profit billion aggreg sector net profit
billion previou year
ebit billion aggreg sector ebit
billion previou year
mcap billion aggreg sector mcap
billion previou year
earn yield time bond yield
price-to-earnings versu sector averag
market averag estim share trade
current year price-to-earnings forward year price-to-earnings
rel yield stock defin yield
divid averag yield dividend yield stock
suggest stock
under-valued dividend yield term
return equiti versu sector averag
market averag
total liabilities/ebitda less compar
favour joseph piotroski benchmark
return asset versu sector averag
market averag
return capit employ versu sector averag
market averag
net profit margin averag last year
consid superior suggest high margin safeti
per du pont analysi return equiti high
comput net profit margin time
asset turnov sales/asset time leverag factor
total assets/sharehold equiti
improv last year
trail twelv month price-to-earnings cyclic
adjust price earn cape cape
develop economist robert shiller base methodolog
benjamin graham david dodd smooth earn
across period base move averag
dividend yield time triple-a bond yield
benchmark set benjamin
growth quarterli revenu net incom
previou correspond period pcp quarterli revenu
million million
previou correspond period pcp quarterli net profit
million million
ebit margin posit increas
past year
return equiti
return asset
fall rise last three month number fall
outnumb rise
last trade session net declin
stock retreat twelv time biggest
one day declin juli
nyse market stock unit trade
today stock rel strength
indic trail market
indic exponenti move averag ema
minu ema neg suggest
past day ratio time
suggest downsid map lower
map bearish indic
map decreas decreas
stock overbought accord
indic
price/sal versu sector averag market
averag estim share trade
current year price/sal forward year price/sal
price book higher averag
total nyse market estim share trade
current year price book forward year price
book
 ratio defin jame tobin mcap divid
total asset compar rest market
stock overvalu rank bottom quartil stock
valu ratio
averag annual compound return share price
last year under-perform averag
annual compound return
earn yield less benchmark yield
price book valu
volum index average
stock trade low high
averag daili volatil place stock
quartil market mean mildli volatil
result report
us million except per share data share outstand
allianc revenu
good servic sold
sell gener administr expens
research develop expens
cost expens
incom loss continu oper equiti
net incom loss includ portion attribut
net incom loss attribut non-controlling interest
net incom loss attribut parent
statement comprehens incom abstract
net incom loss includ portion attribut
loss reclassif tax
comprehens incom loss defin benefit
reclassif adjust tax
sale adjust tax
transact translat gain loss aris period
net tax
comprehens incom loss net tax includ portion
attribut non-controlling interest
comprehens incom loss net tax attribut
comprehens incom loss net tax attribut parent
cash equival
properti plant equip
capit excess par valu stock
accumul comprehens loss
less cost treasuri stock
stockhold equiti attribut non-controlling interest
total liabil equiti
adjust reconcil net incom loss provid
use oper activ abstract
depreci deplet amort
impair long-liv asset dispos
pension settlement amort
divestitur gain royalti
increas decreas oper asset liabil
increas decreas receiv
increas decreas inventori
increas decreas account payabl
increas decreas incom tax payabl
increas decreas oper asset liabil
net provid use oper activ
proce sale matur debt secur available-for-
payment acquir market secur
payment acquir properti plant equip
divestitur proce
payment acquir busi net acquir
net provid use invest activ
proce repay short-term debt
proce issuanc long-term debt
repay long-term debt
payment repurchas common stock
payment dividend
proce payment financ activ
net provid use financ activ
effect exchang rate equival
equival period increas decreas
equival begin period
equival end period
quarterli report sequenti growth
nyse announc ep quarter-end june sequenti
previou quarter
sequenti growth ep
sequenti growth revenu
sequenti growth net profit
compar previou correspond period pcp year-over-year ep revenu
net profit
pcp growth ep
pcp growth revenu
pcp growth net profit
result report annual
us million except per share data share outstand
allianc revenu
product sold
market sell administr
research develop
provis incom tax
net earn attribut bm
cash equival
prepaid expens
properti plant equip
pension liabil
author million share issu outstand
liquid valu per share
common stock par valu per share author billion
share billion issu
capit excess par valu stock
accumul comprehens loss
less cost treasuri stock million common share
million common share
total liabil equiti
adjust reconcil net earn net cash provid
depreci amort net
pension settlement amort
divestitur gain royalti
loss/ gain equiti invest
chang oper asset liabil
net provid oper activ
sale matur market secur
purchas market secur
divestitur proce
acquisit payment
net use /provid invest activ
issuanc long-term debt
repay long-term debt
repurchas common stock
net use financ activ
effect exchang rate equival
increas equival
equival begin year
equival end year
earn cont op margin
annual report bristol myer squibb net profit
nyse report net profit year-end decemb
previou year
major chang compar previou year
total revenu
ebit margin
ebit total asset
good sold sale
profit tax sale
sale market expens sale
debt equiti
total liabil total asset
work capit total asset
retain earn total asset
total current asset total asset
net tangibl asset per share
total non-curr asset total asset
current debtor total asset
fix asset total asset
total revenu total asset steadi
tax expens sale
current ratio steadi
intang total asset
year-on-year comparison per share figur
year-on-year comparison perform ratio
total debt net tangibl asset
total liabil ebitda
total liabil oper
current ratio
common size ratio asset
total non-curr asset total asset
total current asset total asset
intang total asset
current debtor total asset
fix asset total asset
common size ratio sale
good sold sale
profit tax sale
sale market expens sale
tax expens sale
five-year record growth perform
last year total revenu averag ebitda averag net profit averag compound annual
growth rate compound-annual-growth-rate averag total revenu net profit ebitda
five-year record ebitda oper profit net profit roe roa roce
net profit margin average figur
return equiti
return asset
return capit employ
profit tax
oper cash flow
sale
past year incom tax profit tax increas
base issu equiti share market
capitalis billion nyse largest
compani total revenu
june bristol-my squibb provid updat pend
merger celgen
today provid updat approv process timelin
compani pend merger celgen corpor
celg compani remain activ engag
discuss feder trade commiss ftc
ftc continu review propos transact
today announc quarterli dividend
per share record date friday juli
payabl thursday august
detail click
detail click
commiss approv pend acquisit celgen
today announc european commiss ec
grant uncondit approv bristol-my squibb pend
acquisit celgen corpor celg
clearanc european commiss import
mileston toward complet combin celgen
move us one step closer creat lead biopharma
compani well posit develop deliv innov
meaning medicin patient said giovanni caforio
chairman chief execut offic bristol-my squibb
transact remain subject addit customari close
condit regulatori approv
detail click
june catal purchas bristol-my squibb
manufactur facil anagni itali
bristol-my squibb maintain strateg presenc itali
on-going develop commerci new
continu manufactur product bristol-my
squibb offer custom access state-of-the-art
steril biolog fill/finish oral solid manufactur
compani nyse inc
detail click
appoint michel lind evp gener counsel
virpax compani special develop pharmaceut
product pain manag today announc
appoint michel lind compani execut
vice presid gener counsel corpor secretari
ms year in-hous privat legal
practic experi focu global life scienc
detail click
juli result oper
juli bristol-my squibb compani
compani issu press releas earn press
releas announc financi result second quarter
copi earn press releas furnish
pursuant item exhibit current report
incorpor refer herein entireti
detail click
today report result second quarter
highlight strong sale eliqui apixaban opdivo
nivolumab robust oper perform across
good second quarter deliv strong
financi result also advanc integr plan
acquisit celgen said giovanni caforio
chairman chief execut offic bristol-my squibb
detail click
june bristol-my squibb announc result
second quarter juli
part meet co-primari endpoint overal surviv
new york -- -- bristol-my squibb compani nyse
announc result second quarter thursday
juli confer call et juli
compani execut review financi inform
address inquiri investor analyst
investor gener public invit listen live
webcast call http //investor bm com dial
detail click
opinion recommend approv emplic elotuzumab
pomalidomid low-dos dexamethason
treatment patient relaps refractori multipl
nyse today announc committe medicin
product human use chmp european medicin
agenc adopt posit opinion type-ii variat
applic emplic elotuzumab plu pomalidomid low-
dose dexamethason epd treatment adult patient
relaps refractori multipl myeloma receiv
least two prior therapi includ lenalidomid
proteasom inhibitor pi demonstr diseas
progress last therapi
detail click
part meet co-primari endpoint overal surviv
compani nyse today announc part
co-primari endpoint overal surviv os demonstr
superior benefit versu chemotherapi first-lin non-smal cell
detail click
juli bristol-my squibb provid updat part
compani nyse today announc part
phase checkmat trial meet primari endpoint
overal surviv os opdivo regist nivolumab plu
chemotherapi versu chemotherapi patient first-lin
statu hr ci
detail click
part phase checkmat trial evalu
yervoy regist ipilimumab met co-primari endpoint
chemotherapi first-lin non-smal cell lung cancer nsclc
detail click
juli bayer bristol-my squibb ono
pharmaceut enter clinic collabor agreement
investig stivarga regorafenib opdivo nivolumab
combin therapi patient metastat colorect
whippani princeton osaka japan
nyse co ltd ono
announc today three compani enter
clinic collabor agreement evalu combin
bayer kinas inhibitor stivarga regorafenib bristol-my
nivolumab patient micro-satellit stabl metastat
colorect cancer mss mcrc common form
regorafenib monotherapi demonstr overal
surviv benefit versu placebo pivot phase correct
studi shown activ irrespect micro-satellit statu
retrospect analysi studi though limit
respons despit progress treatment
includ advanc effect immuno-oncolog i-o
treatment certain subset around
patient mss tumor i-o monotherapi treatment
approach shown limit thu need
remain encourag earli data seen
combin regorafenib nivolumab
detail click
juli ambrx receiv mileston payment bristol-
myer squibb initi phase clinic trial
san diego juli -- ambrx inc today announc
bristol-my squibb compani bm initi phase
clinic trial evalu safeti pharmacokinet
pharmacodynam long-act relaxin potenti
treatment heart failur hf long-act relaxin
detail click
juli heat biolog complet enrol phase
therapi design activ patient immun system
cancer today announc complet recruit
enrol phase studi investig
combin bristol-my squibb checkpoint
inhibitor nivolumab opdivo merck pembrolizumab
detail click
squibb issu press releas announc consumm
sale upsa consum health busi
transact taisho pharmaceut hold co ltd
taisho bristol-my squibb taisho enter relat
transact agreement close transact includ
detail click
juli bristol-my squibb complet divest
announc today effect juli complet
previous announc divest consum health
busi upsa co ltd taisho
largest over-the-count drug compani japan
divestitur part bristol-my squibb strategi
simplifi realign busi portfolio address chang
busi futur requir evolv pipelin
detail click
extens expir date exchang offer
bristol-my squibb announc today extens
expir date offer exchang exchang offer
note celgen note issu celgen corpor
celg celgen
aggreg princip amount new note issu bristol-
myer squibb compani bristol-my squibb note
cash relat consent solicit consent
solicit made bristol-my squibb behalf
celgen adopt certain propos amend
amend indentur govern celgen note
detail click
june bristol-my squibb announc result
checkmat studi evalu opdivo nivolumab
first-lin treatment patient unresect
compani nyse today announc top-line result
nivolumab versu sorafenib first-lin treatment patient
unresect hepatocellular carcinoma trial
achiev statist signific primari endpoint
overal surviv os per pre-specifi analysi
detail click
data phase trial emplic elotuzumab
pomalidomid dexamethason patient
relaps refractori multipl myeloma rrmm
descript analysi addit emplic pomalidomid
dexamethason reduc risk death among
patient rrmm
benefit month
nyse today announc present updat data
intern random phase studi
evalu emplic elotuzumab plu pomalidomid
dexamethason epd versu pomalidomid dexamethason
pd alon patient relaps refractori multipl
detail click
today announc futur leadership team combin
compani effect upon complet compani pend
merger celgen corpor celg
compani evolv key aspect
commerci structur drive continu growth
highli success market portfolio maxim six near-term
launch opportun deliv valu combin
pipelin guid continu mission serv patient
seriou diseas
detail click
june bristol-my squibb take part goldman
new york -- -- bristol-my squibb compani nyse
take part goldman sach annual global healthcar
confer tuesday june rancho palo
commerci offic answer question compani
detail click
june five-year surviv observ longest follow-up
date advanc melanoma patient treat
combin opdivo nivolumab yervoy ipilimumab
five-year follow-up analysi phase studi
provid evid long-term surviv follow discontinu
treatment patient advanc melanoma
analys phase checkmat studi provid new long-
term qualiti life data opdivo alon combin
nyse today announc updat result studi
evalu opdivo nivolumab yervoy ipilimumab alon
combin patient advanc metastat
detail click
result opdivo nivolumab yervoy ipilimumab
combin advanc hepatocellular carcinoma
opdivo plu yervoy yield object respons rate
median durat respons month
data demonstr potenti immuno-oncolog combin
fourth common caus cancer death world-wide
nyse today announc first result opdivo
nivolumab plu yervoy ipilimumab cohort phase
checkmat studi evalu immuno-oncolog
combin patient advanc hepatocellular carcinoma
previous treat sorafenib
detail click
vivacita oncolog medic advisor
promin research sloan-kett bristol-mey
vivacita compani continu confirm merit
effort week-when dr luigi lenaz join compani
medic advisor
detail click
extens expir date exchang offer
bristol-my squibb announc today extens
expir date offer exchang exchang offer
note celgen note issu celgen corpor
celg celgen
aggreg princip amount new note issu bristol-
myer squibb compani bristol-my squibb note
cash relat consent solicit consent
solicit made bristol-my squibb behalf
celgen adopt certain propos amend
amend indentur govern celgen note
detail click
may event calendar heat biolog present
therapi design activ patient immun system
cancer today announc present
annual riley fbr institut investor confer
thursday may pm pst beverli hilton
detail click
may bristol-my squibb present new data
type cancer across oncolog portfolio
eha
new data opdivo nivolumab plu yervoy ipilimumab
patient advanc hepatocellular carcinoma
melanoma patient symptomat brain metastas
new long-term surviv data health outcom research
opdivo combin yervoy advanc melanoma
eighteen-month efficaci result emplic elotuzumab plu
pomalidomid low-dos dexamethason
detail click
may award-win actor produc sterl
brown join bristol-my squibb effort share stori
like live cancer today
award-win actor produc sterl brown join
bristol-my squibb effort share stori like
live cancer today survivorship today aim shed light
long-term impact live cancer
us black panther partner bristol-my
squibb seri design illumin triumph
challeng life cancer diagnosi
detail click
may bristol-my squibb take part ub global
new york -- -- bristol-my squibb compani nyse
take part firesid chat ub global healthcar
confer tuesday may new york giovanni
caforio chairman chief execut offic answer
question et
investor gener public invit listen live
webcast session http //investor bm com
detail click
vero beach fl may quinton charl oswald
well-known entrepreneur three decad
experi big pharma biotech quinton oswald born
rais south africa start career
bristol myer
work bristol myer year reloc
holland play major role merg bristol myer
squibb form
time held leadership posit differ
novarti genentech sarcod
checkmat studi primari endpoint
overal surviv opdivo nivolumab radiat
patient newli diagnos mgmt-unmethyl
nyse today announc phase checkmat trial
temozolomid plu radiat patient newli diagnos
glioblastoma multiform gbm meet primari endpoint
overal surviv os final analysi
may bristol-my squibb compani price billion
bristol-my squibb today announc price
previous announc privat offer offer senior
unsecur note combin aggreg princip amount
billion collect note note issu
nine tranch aggreg princip amount
float rate note due ii aggreg
princip amount float rate note due iii
aggreg princip amount note
due iv aggreg princip amount
note due aggreg
princip amount note due vi
aggreg princip amount note due vii
aggreg princip amount note
due viii aggreg princip amount
note due ix aggreg
princip amount note due
jose baselga resign bristol myer squibb
director resign take effect sep
boerner execut vice presid august
appoint christoph boerner
execut vice presid appoint take effect aug
report buy sell trail month continu
share
report institut buy sell share
hold end quarter
report hold institut march
total report hold institut share
report hold institut
issu capit
net buying/ sell institut trail month ttm
usd valu
montreal
majesti queen right
provinc alberta
state tennesse treasuri
america corp de
new patent issu us pto
view detail click patent link
aryl dihydropyridinon piperidinon inhibitor
method treatment use mutant molecul
method treat inflamm bispecif antibodi
cyclic compound use modul tnf alpha
pyrimidinon factor xia inhibitor
inhibitor indoleamin method use
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
tricycl heterocycl compound use inhibitor tnf
cancer immunotherapi disrupt signal
substitut inhibitor
phosphin oxid alkyl amid substitut heteroaryl compound modul and/or ifn
seco-cyclopropapyrroloindol compound antibody-drug conjug thereof method make
use
antibody-drug conjug tubulysin analog enhanc stabil
imidazopyridazin compound use modul and/or ifn- alpha respons
tricycl sulfon ror gamma modul
fibronectin base scaffold protein improv stabil
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
stabl subcutan protein formul use thereof
modifi relaxin polypeptid compris pharmacokinet enhanc use thereof
optim antibodi bind lymphocyt activ use thereof
devic method test inspect integr contain
anti-ico agonist antibodi use thereof
fibronectin base scaffold domain protein bind myostatin
treatment waldenstroom macroglobulinemia
thiazolyl- thiadiazolyl-substitut pyridyl compound use kinas inhibitor
method treat cancer administ igf-ir bind molecul
fc fusion protein compris novel linker arrang
quinazolin potassium ion channel inhibitor
triazolopyridin inhibitor myeloperoxidas
substitut aza benzofuran compound treatment hepat
substitut tetrahydroisoquinolin compound factor xia inhibitor
macrocycl factor xia inhibitor
ipilimumab variant enhanc adcc
method treat immun diseas administ antibodi polypeptid specif bind
carbazol compound use bromodomain inhibitor
therapeut use modifi polypeptid
antibodi tigit
compound anti-cancer agent
fuse pyridin kinas inhibitor
quinuclidin compound nicotin acetylcholin receptor ligand
treatment melanoma use antibodi antibodi
antibodi
diamid macrocycl factor xia inhibitor
compound treatment hepat
antibodi bind peptidoglycan recognit protein
method select bind protein
compound use immunomodul
cancer immunotherapi disrupt signal
benzofuran substitut primari benzamid hcv inhibitor
cyclic urea inhibitor rock
benzofuran compound treatment hepat
benzofuran substitut bicycl secondari benzamid hcv inhibitor
lactam inhibitor rock
five-memb heterocycl use serin proteas inhibitor
tricycl compound anti-cancer agent
heterocycl compound use inhibitor tnf
apj agonist
substitut tetrahydrocarbazol carbazol carboxamid compound
process intermedi make tubulysin analog
antibodi use thereof
benzofuran substitut secondari benzamid hcv inhibitor
diamid macrocycl fxia inhibitor
combin antibodi antibodi treat tumor
tubulysin analog method make use
antibodi use thereof
carbamoyloxymethyl triazol cyclohexyl acid lpa antagonist
mammalian cell cultur process protein product
method treat dermatomyos polymyos administ solubl molecul
carbazol compound use bromodomain inhibitor
imidazothiadiazol imidazopyrazin deriv proteas activ receptor inhibitor
treat platelet aggreg
mammalian cell cultur process protein product
heteroaryl substitut pyridyl compound use kinas modul
heteroaryl substitut pyrrolotriazin amin compound inhibitor
carbazol tetrahydrocarbazol compound use inhibitor btk
antibodi use thereof
pyrrolidin modul treatment diseas diabet
bristol-my squibb compani bm engag discoveri develop licens manufactur market
distribut sale pharmaceut nutrit product compani two segment pharmaceut
nutrit segment made global pharmaceut intern consum
medicin busi nutrit segment consist mead johnson nutrit mead johnson primarili
infant formula children nutrit busi januari compani complet divestitur bristol-
myer squibb medic imag medic imag avista capit partner june bm acquir kosan
bioscienc inc develop oncolog product august compani complet divestitur
convatec busi cidron healthcar limit affili nordic capit fund vii decemb
bm complet sale brand busi egypt glaxosmithklin
board manag creation sharehold valu
board director year sinc appoint
giovanni caforio chief execut offic bristol-
myer squibb sinc may serv
compani board director sinc june may
assum role chairman board
ceo giovanni led compani focu research
develop transform medicin includ
lead portfolio immunotherapi fundament
chang way cancer treat leadership bm
evolv oper model order increas speed
background physician giovanni help
strengthen compani patient-focus cultur -- one driven
innov speed account passion leader
focus busi valu compani cultur
promot reward divers inclus
prior becom ceo giovanni serv chief oper
offic respons lead fulli integr world-wide
commerci organ companywid function
enterpris servic global manufactur suppli
preced work compani chief commerci
giovanni join bristol-my squibb vice presid
gener manag itali world-wide medicin group
assum ad respons greec israel
south east europ appoint
senior vice presid european market brand
commerci reloc us assum
role senior vice presid oncolog
oncolog immunolog becom presid
compani organ prior join bristol-
myer squibb giovanni spent year
number leadership posit
born educ itali giovanni receiv
univers rome
charl bancroft respons compani world-wide
financ oper includ controllership area tax
treasuri audit servic procur strateg initi
global commerci manufactur financ
oper charli also respons busi
develop strategi allow integr approach
financi plan busi develop strategi
support compani effect meet long-term
goal charli join compani kpmg
sinc held posit increas respons within financ
organ includ intern assign
commerci oper respons latin american
east africa canada japan sever countri
pacif rim charli receiv bachelor scienc degre
account drexel univers master busi
administr templ univers
dr vousden age senior group leader
franci crick institut london sinc februari chief
scientist cancer research uk cruk sinc juli
serv director cruk beatson
institut glasgow prior held leadership role
nation cancer institut maryland
dr vousden bring board year
experi lead ground break cancer research
fellow royal societi serv member
scientif advisori board centro nacion de investigacion
oncologica grail inc ludwig institut cancer research
pmv pharma swiss institut
experiment cancer research dr vousden also council
member european molecular biolog organ
mr storch age serv chief execut offic
oper depart store includ sak fifth avenu
outfitt sak kaufhof inno e-commerc
busi gilt novemb januari serv
chairman chief execut offic storch advisor
also serv chairman toy us inc februari
novemb chief execut offic toy us
februari may prior join toy us mr
storch serv vice chairman target corpor join
senior vice presid strategi serv
role increas senior next year prior
join mr storch partner mckinsey compani
director fanat inc
skill experi retail veteran
year experi mr storch provid board valuabl
busi leadership manag insight includ
expertis lead organ global oper give
keen understand issu face multi-national
busi qualiti make valu member
audit committe addit prior servic
compens committe anoth public compani posit
well serv member compens
dr sato age serv chairman board denali
therapeut inc previous serv professor
manag practic harvard busi school juli
juli juli octob serv
professor practic molecular cell biolog
dr sato retir presid vertex pharmaceut
incorpor global biotechnolog compani
respons research develop busi
corpor develop commerci oper legal
financ dr sato also serv chief scientif offic senior
vice presid research develop chair
scientif advisori board vertex name presid
serv chairman inc
board director inc
peer health exchang inc serv co-chair
task forc scienc engin harvard univers
co-chair advisori council lifesci nyc
mr grobstein age retir vice chairman ernst
young llp independ regist public account firm mr
grobstein work ernst young
admit partner
serv vice chairman intern oper
vice chairman plan market
industri servic vice chairman
account audit servic
serv board truste execut committe
treasur central park conserv
also serv board director peer health
mr paliw age serv chairman presid
chief execut offic harman intern industri inc
connect technolog compani automot consum
enterpris market sinc juli mr paliw serv
presid chief execut offic harman sinc juli
prior join harman mr paliw serv member
group execut committe abb ltd provid industri
autom power transmiss system servic
januari june
mr paliw also serv presid global market
technolog abb ltd januari june
chairman chief execut offic abb north america
januari june presid chief
execut offic abb autom technolog divis
octob decemb
mr paliw serv board busi advisori council
farmer school busi miami univers
india busi council usibc board director also
member ceo busi roundtabl washington
 india ceo forum
mr arduini age presid chief execut
offic integra lifesci hold corpor global
medic technolog compani sinc januari current
serv member integra board director serv
presid chief oper offic integra novemb
januari join integra mr arduini
corpor vice presid presid medic deliveri
baxter healthcar prior join baxter mr
arduini work gener electr healthcar spent
much year varieti manag role
domest global busi culmin lead global
function imag busi mr arduini also serv board
director advam advanc medic technolog
associ board director mdic medic devic
innov consortium board director
skill experi year healthcar
industri mr arduini bring board extens leadership
busi oper experi particularli respect
manufactur sale medic technolog devic
addit mr arduini experi serv public compani
chief execut offic former chief oper offic
posit well serv member audit committe
serv chief execut offic shire plc
chairman board also
serv director incorpor
chairman presid chief execut offic
director mr
emmen serv presid world-wide pharmaceut
merck kgaa chief execut offic
commerci oper astra merck inc
sale market administr posit merck
co inc
skill experi year
biopharmaceut industri mr emmen bring board
signific expertis manag busi develop
busi oper particularli respect strategi
team effect mr emmen strong leadership qualiti
industri knowledg posit well provid valuabl insight
manag fellow board member issu
face compani serv member
compens manag develop committe
member scienc technolog committe
mr laci age former non-execut chairman dave
buster entertain inc previous serv
chairman chief execut offic sear roebuck co
vice chairman chief execut offic
successor sear hold corpor
sandi leung serv legal advisor board director
compani execut respons shape
compani legal strategi sandi also respons
secur philanthropi
mr laci also serv vice chairman sear hold
corpor recent mr laci serv
senior advisor oak hill capit partner privat
equiti invest firm
truste fidel fund california chapter
mr laci director center advanc studi
behavior scienc stanford univers
mr robert bertolini cpa independ director
compani mr bertolini serv presid chief
offic bausch lomb incorpor februari
august acquisit
previous serv execut vice presid chief
financi offic schering-plough corp novemb
novemb merger merck co
respons tax account financi asset
manag prior join schering-plough mr bertolini spent
year pricewaterhousecoop llp ultim lead
acceler pace scienc government polici
regul overal global complex across industri
requir us even agil ever say sandi
legal team bring strateg valu across aspect
busi practic sound counsel guid
compani mission help patient
sandi join bristol-my squibb staff attorney
litig depart becam assist counsel
one year later name associ counsel
sandi appoint posit counsel corpor
secretari appoint act gener counsel
name gener counsel sandi
name execut vice presid
prior join compani sandi prosecutor
advic aspir manag posit
good will hard work
bring good excel judgment expertis tabl
import must great person integr
someon peopl trust peopl trust feel
comfort seek advic also respect peopl
superior everyon
sandi earn law degre boston colleg law
bachelor degre tuft univers
dr lynch serv chairman chief execut offic
massachusett gener physician organ member
massachusett gener hospit board sinc
dr lynch director yale cancer center
richard jonathan sackler professor intern
medicin yale cancer center yale school medicin
also serv physician chief smilow cancer hospit
yale-new sinc prior dr lynch
professor medicin harvard medic school chief
hematology/oncolog massachusett gener hospit dr
lynch member american associ cancer
research american societi clinic oncolog
intern associ studi lung cancer
ann powel judg global head human resourc
bristol-my squibb whose mission discov develop
deliv innov medicin help patient prevail
seriou diseas ann direct respons drive
corpor global capabl talent manag cultur
organiz effect tie directli busi
perform ann work across enterpris support bristol-
myer squibb commit creat energ work
experi cultur power divers broadli
inclus individu encourag exceed
potenti inspir make innov contribut
patient global commun live work
courag passion workforc truli inspir
drive even higher level engag make differ
live patient say ann ann industri experi
expertis lie execut compens leadership develop
chang manag diversity/inclus train design
deliveri talent acquisit labor relat merger
acquisit divestitur start-up
karen santiago appoint senior vice presid control
compani effect februari join bristol-
myer squibb compani serv multipl role
increas respons recent
serv vice presid financ global manufactur
suppli vice presid financ us
puerto rico commerci sinc vice
presid lead enabl function financ
transform ms santiago financ
 account certifi public account
mr joseph caldarella senior vice presid corpor
control bristol-my squibb co vice
presid corpor control vice
compani
technolog organ posit compani success
rapidli evolv digit age focus ensur
compani inform asset oper reliabl
access secur drive digit compani
adopt new approach digit health continu
innov approach long-term partnership key servic
excit time lead team advanc
technolog provid new opportun streamlin live
unpreced way includ manag health paul
said deliv digit capabl acceler compani
work bring innov medicin patient
challeng honor
throughout experi domest intern high-
tech consum packag good biopharmaceut
compani paul career focus strateg
leverag inform technolog drive superior perform
join bristol-my squibb paul held posit kraft
gener food hewlett-packard member
research board serv board truste
paul bachelor degre electr engin
master degre comput scienc steven institut
technolog complet program manag
develop harvard busi school program
leadership develop imd switzerland
price period/numb period
price close today/pric close period ago rank
percentil within entir market
report report prepar minkabu infonoid inc minkabu analyst opinion project report
suppli global market intellig llc compani profil company-rel inform co-own
minkabu infonoid inc pk clean ltd buysellsign group compani stock index price suppli
stock exchang tradeg exchang euronext deutsch brse ag bme stuttgart stock exchang tradeg exchang
exchang clear limit taiwan stock exchang tokyo stock exchang nagoya stock exchang toronto stock exchang
express opinion analyst sole person opinion author contributor report minkabu
respons accuraci complet reliabl timeli inform opinion respons error
omiss therein assum liabil direct indirect loss damag particular lost profit may
incur result relianc inform use report inform report may contain project
opinion assumpt estim forecast relat futur busi perform event intend exampl
repres predict minkabu current futur perform compani secur
minkabu make warranti regard accuraci reliabl project opinion assumpt estim forecast
liabil damag kind aris relianc inform forward-look statement guarante
futur perform involv risk uncertainti actual result may differ forward-look statement result
variou factor minkabu oblig updat correct inform report constitut recommend
make invest purchas sell specif invest product report intend give financi
invest advic conduct care independ analysi seek advic profession advisor
suitabl invest need minkabu express opinion compani secur invest
product fluctuat futur perform thereof stock price rate comment includ target price buy
sell hold creat aggreg opinion individu investor opinion analyst secur
compani rate overvalu under-valued fairlyvalu fair stock price other display ancillari
rate object fact base statist record minkabu express opinion compani secur
invest product fluctuat futur perform thereof therebi either
minkabu repres warrant report appropri avail view download locat
exclus respons complianc applic local law regul view download report report
intend use inform refer purpos constitut solicit offer make
invest purchas sell specif invest product
minkabu regist broker dealer invest advisor analyst invest banker underwrit minkabu may hold
secur refer report includ deriv instrument may busi relat compani discuss
herein without prior written consent minkabu reproduct copi transmiss transfer distribut public
similar action content report shall made
